High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
暂无分享,去创建一个
John D. Shaughnessy | Bart Barlogie | G. Mulligan | F. Zhan | B. Barlogie | J. Shaughnessy | B. Bryant | Fenghuang Zhan | George Mulligan | Barb Bryant
[1] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[2] P. L. Bergsagel,et al. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature , 2008, Leukemia.
[3] K. Koike,et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. , 2007, Blood.
[4] J. Downing,et al. Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .
[5] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[6] M. Woodruff,et al. Immune Response , 1969, Nature.
[7] E. Lanino,et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. , 2005, Blood.
[8] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[9] J. Okamura,et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group , 2002, Leukemia.
[10] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[11] L. Staudt,et al. Signatures of the immune response. , 2001, Immunity.
[12] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.